SecBot SecBot
Biotech Drug Report Generated Aug 18, 2026

NVL-330

GSK·GSK plc
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1
Time to market
Unknown, early Phase 1; realistically several years from approval if it survives, and most Phase 1 oncology drugs do not reach the market.
Why 2/10
NVL-330 is a Phase 1 program inside a ~$100B company with no scheduled PDUFA, pivotal readout, or other dated binary in the next ~12 months, it is a small part of a large pipeline, so it cannot score above 2 on the impact rubric.
Actionable Insight NEUTRAL

For GSK (GSK) investors, NVL-330 is not a tradeable near-term catalyst, ignore it for the next year and instead track GSK's other acquired assets (neladalkib PDUFA Nov 27, 2026; zidesamtinib label expansion) and GSK's Q2-reaffirmed guidance. The only event to watch for NVL-330 specifically is early Phase 1 dose-escalation data at an oncology congress, for which no date was found in any source.

Price Chart

Loading chart...

Executive Summary

NVL-330 is a Phase 1 HER2-selective inhibitor for HER2-altered (mutant) non-small cell lung cancer (NSCLC) that GSK plc acquired when it closed its ~$10.6B all-cash takeover of Nuvalent on July 15, 2026 ($124.00/share; Nuvalent, formerly NUVL, is now delisted). It is the third and earliest-stage asset in a targeted-lung-cancer trio GSK bought, alongside zidesamtinib (Jideytro, ROS1+ NSCLC, FDA-approved July 2026) and neladalkib (ALK+ NSCLC, FDA decision expected Nov 27, 2026). For GSK shareholders NVL-330 is currently immaterial to the share price; it matters only as long-option pipeline value.

How It Works

NVL-330 is a daily pill (small-molecule tyrosine kinase inhibitor) designed to block HER2, a cell-growth protein that is abnormally activated by mutations in a subset of lung cancers. By selectively shutting down mutated HER2 while largely sparing closely related proteins, the drug aims to stop HER2-mutant tumors from growing, the same class strategy as GSK's other new lung-cancer assets (which target the ROS1 and ALK growth signals) but aimed at the HER2 mutation.

Trial Status

Phase 1 development for HER2-altered NSCLC, per the June 9, 2026 Nuvalent 8-K describing the GSK deal ("plus a phase I HER2 inhibitor"). No Phase 2/3 ClinicalTrials.gov record, FDA action, or dated readout for NVL-330 exists in the tool data; no clinical data were cited in any source retrieved.

The Two-Sided Case

▲ Bull Case3
Part of a strategic, already-closed $10.6B GSK acquisition (announced June 9, 2026; closed July 15, 2026 at $124.00/share cash) that builds a three-asset targeted-NSCLC franchise, the deal validation is done and GSK has the balance sheet to fund it (~$100B market cap).
HER2-mutant NSCLC is a defined genetic subset with a real need for selective oral HER2 inhibitors, and a HER2-selective TKI slots into an increasingly strong driver-focused lung-cancer portfolio alongside approved/under-review ROS1 and ALK drugs.
The same acquired portfolio has already delivered an FDA approval (Jideytro/zidesamtinib, approved July 2026 ahead of its PDUFA), suggesting GSK's integration and regulatory execution on these assets is working.
▼ Bear Case4
Very early stage: NVL-330 is only Phase 1 with no clinical efficacy data in any source reviewed, typical Phase 1 attrition risk means a high probability it never becomes a commercial product.
Immaterial to GSK's stock near term: it is one small program inside a ~$100B company with no scheduled binary catalyst, so it cannot drive the share price by itself.
Deal drag: GSK guided to low single-digit EPS dilution from the Nuvalent deal through FY2028 and took a £1.9B impairment hit in Q2 2026 (largely the failed camlipixant trial), underscoring both the cost of the acquisition and GSK's overall pipeline-execution risk.
Competitive field: HER2-mutant NSCLC is already served by approved HER2-targeted therapies, so NVL-330 would need to demonstrate meaningfully better efficacy/tolerability in later trials to win share.

Upcoming Catalysts

  • None dated for NVL-330 itself in the next 12 months (no PDUFA, pivotal readout, or scheduled data presentation found).
  • Context catalysts from the same acquired portfolio: neladalkib FDA PDUFA target action date Nov 27, 2026 (per local FDA catalyst data, ticker RPRX royalty stream).
  • Any GSK disclosure of NVL-330 Phase 1 dose-escalation/early efficacy data at future oncology conferences, no confirmed date.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GSK plc 6-K GSK ·Originating report

Sources · 5

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 sec.gov